The Center for Biosimilars® recaps the top news for the week of May 13, 2019.
Transcript
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of May 13.
Number 5: The Generic Biosimilar Medicines Association has launched an educational hub for biosimilars.
Number 4: Biosimilar developer Biocon said this week that it will share in the global profits of Hulio, an adalimumab biosimilar.
Number 3: Set against a backdrop of rising concern about the cost of insulin, the FDA held a hearing about biosimilar insulins.
Number 2: Last week, the FDA released its long-awaited final guidance on demonstrating interchangeability of a biosimilar with its reference.
Number 1: AbbVie announced that it has settled its patent litigation with Boehringer Ingelheim over adalimumab.
Finally, last week, our e-newsletter asked how comfortable you think patients and providers should be about switching among biosimilars of the same product.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.